EDAP TMS SA FOCL
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-5.4
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $70.5M | -$29.2M | $30.0M | — | $19.4M |
| 2024 | $69.4M | -$20.6M | $28.7M | — | $42.5M |
| 2023 | $60.4M | -$21.2M | $24.4M | — | $62.9M |
| 2022 | $55.1M | -$2.9M | $24.2M | — | $71.6M |
| 2021 | $44.1M | $699,890 | $18.4M | — | $50.1M |
| 2020 | $41.7M | -$1.7M | $18.4M | — | $26.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Annen Steven | SVP, Marketing & Product Mgmt. | 2026-05-12 | Grant | 90,000 | — |
| Shah Sanket | Gen Counsel & Corp Secretary | 2026-05-12 | Grant | 67,500 | — |
| Rhodes Ryan | Chief Executive Officer | 2026-05-12 | Grant | 304,500 | — |
| Mobeck Kenneth S. | Chief Financial Officer | 2026-05-12 | Grant | 120,000 | — |
| LEVINE JOSHUA | director | 2026-05-11 | Buy | 10,000 | $4.22 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.4 (distress)
- Working capital / assets 0.253
- Retained earnings / assets -1.628
- EBIT / assets -0.313
- Equity / liabilities 0.326
Source: SEC EDGAR filings · CIK 0001041934 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.